Immune-related adverse events (irAEs) predict therapeutic efficacy of an anti-PD-1 antibody in cancer patients

被引：0
|
作者：
Rogado, J. [1 ]
Romero Laorden, N. [1 ]
Sanchez Torres, J. M. [1 ]
Ballesteros Garcia, A. I. [1 ]
Pacheco-Barcia, V. E. [1 ]
Arranz, R. [2 ]
Mondejar Solis, R. [1 ]
Gullon, P. [3 ]
Lorenzo, A. [4 ]
Colomer Bosch, R. [1 ]
机构：
[1] Hosp Univ La Princesa, Med Oncol, Madrid, Spain
[2] Hosp Univ La Princesa, Hematol, Madrid, Spain
[3] Univ Alcala De Henares, Social & Cardiovasc Epidemiol Res Grp, Madrid, Spain
[4] Hosp Univ Mostoles, Hematol, Mostoles, Spain
来源：
ANNALS OF ONCOLOGY | 2018年 / 29卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1227P
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Immune-related adverse events predict the therapeutic efficacy of anti-PD-1 antibodies in cancer patients
    Rogado, J.
    Sanchez-Torres, J. M.
    Romero-Laorden, N.
    Ballesteros, A., I
    Pacheco-Barcia, V
    Ramos-Levi, A.
    Arranz, R.
    Lorenzo, A.
    Gullon, P.
    Donnay, O.
    Adrados, M.
    Costas, P.
    Aspa, J.
    Alfranca, A.
    Mondejar, R.
    Colomer, R.
    [J]. EUROPEAN JOURNAL OF CANCER, 2019, 109 : 21 - 27
  • [2] Association of efficacy of anti-PD-1 immunotherapy in patients with advanced cancer with immune-related adverse events (irAEs)
    Rogado Revuelta, Jacobo
    Romero-Laorden, Nuria
    Sanchez Torres, Jose Miguel
    Pacheco-Barcia, Vilma
    Ballesteros, Anabel
    Maria Ramos-Levi, Ana
    Arranz, Reyes
    Lorenzo, Alicia
    Gullon, Pedro
    Garrido Garcia, Ana
    Maria Serra, Jose
    Donnay, Olga
    Adrados, Magdalena
    Costas, Pablo
    Aspa, Javier
    Alfranca, Arantza
    Fenor De la Maza, Maria Dolores
    Mondejar, Rebeca
    Colomer, Ramon
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [3] Anti-PD-1 antibodies: immune-related adverse events and efficacy
    [J]. Reactions Weekly, 2019, 1739 (1) : 6 - 6
  • [4] Profiling Immune-Related Adverse Events (irAEs) in Patients with Anti-PD-1 for Advanced Non-Small Cell Lung Cancer
    Toi, Y.
    Sugawara, S.
    Aso, M.
    Tsurumi, K.
    Ono, K.
    Sugisaka, J.
    Shimizu, H.
    Ono, H.
    Domeki, Y.
    Aiba, T.
    Kawana, S.
    Saito, R.
    Terayama, K.
    Kawashima, Y.
    Nakamura, A.
    Yamanda, S.
    Kimura, Y.
    Honda, Y.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S598 - S599
  • [5] Anti-PD-1 immune-related adverse events are associated with high therapeutic antibody fixation on T cells
    Gazzano, Marianne
    Parizot, Christophe
    Psimaras, Dimitri
    Vozy, Aurore
    Baron, Marine
    Abbar, Baptiste
    Fallet, Vincent
    Litvinova, Elena
    Canellas, Anthony
    Birzu, Cristina
    Pourcher, Valerie
    Touat, Mehdi
    Weiss, Nicolas
    Demeret, Sophie
    Roos-Weil, Damien
    Spano, Jean-Philippe
    Lebbe, Celeste
    Salem, Joe-Elie
    Cadranel, Jacques
    Hervier, Baptiste
    Gorochov, Guy
    Guihot, Amelie
    [J]. FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [6] RISK FACTORS OF IMMUNE-RELATED ADVERSE EVENTS IN PATIENTS TREATED WITH ANTI-PD-1 ANTIBODY PEMBROLIZUMAB
    Eun, Y.
    Kim, I. Y.
    Kim, H.
    Ahn, J. K.
    Park, E. -J.
    Hwang, J.
    Jeong, H.
    Chai, J. Y.
    Cha, H. -S.
    Koh, E. -M.
    Lee, J.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : 1205 - 1205
  • [7] Immune-related adverse events with resumed anti-PD-1 therapy
    [J]. Reactions Weekly, 2017, 1676 (1) : 4 - 4
  • [8] Effect of excess weight and immune-related adverse events on the efficacy of cancer immunotherapy with anti-PD-1 antibodies
    Rogado, Jacobo
    Romero-Laorden, Nuria
    Miguel Sanchez-Torres, Jose
    Maria Ramos-Levi, Ana
    Pacheco-Barcia, Vilma
    Isabel Ballesteros, Ana
    Arranz, Reyes
    Lorenzo, Alicia
    Gullon, Pedro
    Garrido, Ana
    Serra Lopez-Matencio, Jose Maria
    Donnay, Olga
    Adrados, Magdalena
    Costas, Pablo
    Aspa, Javier
    Alfranca, Arantzazu
    Mondejar, Rebeca
    Colomer, Ramon
    [J]. ONCOIMMUNOLOGY, 2020, 9 (01):
  • [9] Immune-related adverse events predict the therapeutic efficacy of pembrolizumab in urothelial cancer patients
    Kawai, Taketo
    Sato, Yusuke
    Makino, Katsuhiro
    Yamada, Yuta
    Nomiya, Akira
    Nakamura, Masaki
    Yamada, Daisuke
    Suzuki, Motofumi
    Igawa, Yasuhiko
    Kume, Haruki
    [J]. EUROPEAN JOURNAL OF CANCER, 2019, 116 : 114 - 115
  • [10] Delayed immune-related adverse events (irAEs) on anti-PD1-based therapy
    Owen, C. N.
    Bai, X.
    Quah, T.
    Lo, S.
    Callaghan, S.
    Martinez-Vila, C.
    Bhave, P.
    Reijers, I.
    Gerard, C. L.
    Aspelagh, S.
    Xu, W.
    Welsh, S. J.
    Sandhu, S.
    Mangana, J.
    McQuade, J. L.
    Ascierto, P. A.
    Zimmer, L.
    Johnson, D. B.
    Lebbe, C.
    Menzies, A. M.
    [J]. ANNALS OF ONCOLOGY, 2020, 31 : S761 - S762
12345